An observational study in Haemophilia A, sponsored by Novo Nordisk A/S. Enrolling by invitation at 1 site in Denmark. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Novo Nordisk A/S · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 22nd largest by planned enrollment of the 32 observational ones that give a count, is one of 3 that started in 2020, is one of 32 observational ones, reaches primary completion later than 4 of the 11 other live ones, and was the 73rd registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States, Austria, Belgium and 9 more countries
Ages 18–64 · Men only · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 12+
Novo Nordisk A/S · Sites in India, Malaysia, Korea, Republic of and 1 more country
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2020.
This study's planned enrollment of 50 is below the median of 81 across 311 observational studies indexed under Hemophilia A.
Median enrollment 38 across the 59 interventional studies, 86 across the 32 observational. Of the 78 that completed or were terminated, 20 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
4 of the studies in Hemophilia A by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04682145Novo Nordisk A/SAdverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol | 2026-12-01 |
| NCT07653139Novo Nordisk A/SPatient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany | 2026-12-26 |
| NCT07220564Novo Nordisk A/SA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | 2027-02-05 |
| NCT04574076Novo Nordisk A/SA Study Following Males With Haemophilia A on Prophylaxis With Esperoct® | 2027-06-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This non-interventional study concerns a safety data collection based on adverse event data from a third-party registry (European Haemophilia Safety Surveillance System, EUHASS) that includes information about adverse events from patients with haemophilia A treated with turoctocog alfa pegol. There is no extra burden to the patients by participating in this registry-based data collection.
All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All patients with haemophilia A treated with turoctocog alfa pegol and reporting adverse events to EUHASS.
Drug: Turoctocog alfa pegol
Patients will be treated with commercially available turoctocog alfa pegol according to routine clinical practice at the discretion of the treating physician. A decision to initiate treatment with commercially available turoctocog alfa pegol has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in the registry in scope.
Adverse events (AEs) reported to the registry with suspected relation to turoctocog alfa pegol, Adverse Drug Reactions (ADRs), in patients with haemophilia A for renal, hepatic and neurological events.
Count
Time frame: From start to end of data collection (December 2019 to January 2025)
Other AEs reported to the registry during the study period with suspected relation to turoctocog alfa pegol in patients with haemophilia A
Count. Includes ADRs of special interest (de novo FVIII inhibitors equal to or above 0.6 Bethesda Units (BU)); anaphylaxis and other allergic reactions; thromboembolic events).
Time frame: From start to end of data collection (December 2019 to January 2025)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Dec 2020 (actual). Primary completion is estimated for Dec 2026, 71 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 8, 2026: primary completion Feb 2026 → Dec 2026 and completion Feb 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.